Steinberg Global Asset Management maintained its stake in shares of Cerus Corporation (NASDAQ:CERS) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 89,200 shares of the biotechnology company’s stock at the end of the second quarter. Steinberg Global Asset Management owned about 0.09% of Cerus Corporation worth $224,000 as of its most recent SEC filing.
A number of other institutional investors have also recently bought and sold shares of the company. Salzhauer Michael increased its position in Cerus Corporation by 16.0% in the second quarter. Salzhauer Michael now owns 363,019 shares of the biotechnology company’s stock worth $912,000 after buying an additional 50,000 shares during the period. Stephens Inc. AR increased its position in Cerus Corporation by 0.3% in the first quarter. Stephens Inc. AR now owns 950,729 shares of the biotechnology company’s stock worth $4,231,000 after buying an additional 2,539 shares during the period. Russell Investments Group Ltd. purchased a new position in Cerus Corporation during the first quarter worth about $137,000. Bank of New York Mellon Corp increased its position in Cerus Corporation by 1.3% in the first quarter. Bank of New York Mellon Corp now owns 505,652 shares of the biotechnology company’s stock worth $2,250,000 after buying an additional 6,710 shares during the period. Finally, Point72 Asset Management L.P. purchased a new position in Cerus Corporation during the first quarter worth about $1,828,000. Institutional investors and hedge funds own 62.58% of the company’s stock.
Cerus Corporation (NASDAQ CERS) traded down 0.79% during midday trading on Friday, hitting $2.50. The company had a trading volume of 361,299 shares. The stock has a 50 day moving average price of $2.36 and a 200-day moving average price of $3.31. Cerus Corporation has a 52 week low of $1.93 and a 52 week high of $7.19. The stock’s market capitalization is $272.84 million.
Cerus Corporation (NASDAQ:CERS) last announced its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.16). The company had revenue of $9.53 million during the quarter, compared to the consensus estimate of $9.14 million. Cerus Corporation had a negative return on equity of 120.31% and a negative net margin of 164.39%. Cerus Corporation’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same period in the previous year, the business earned ($0.18) EPS. On average, equities analysts predict that Cerus Corporation will post ($0.68) EPS for the current year.
ILLEGAL ACTIVITY WARNING: This news story was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://stocknewstimes.com/2017/08/19/steinberg-global-asset-management-has-224000-position-in-cerus-corporation-nasdaqcers-updated-updated.html.
Several equities analysts have recently weighed in on CERS shares. Cantor Fitzgerald set a $7.00 price target on Cerus Corporation and gave the company a “buy” rating in a report on Tuesday, May 23rd. Zacks Investment Research upgraded Cerus Corporation from a “sell” rating to a “hold” rating in a report on Tuesday, June 27th. BTIG Research restated a “buy” rating and set a $5.00 price target on shares of Cerus Corporation in a report on Sunday, May 28th. ValuEngine downgraded Cerus Corporation from a “sell” rating to a “strong sell” rating in a report on Saturday, June 17th. Finally, BidaskClub upgraded Cerus Corporation from a “sell” rating to a “hold” rating in a report on Tuesday, August 8th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $7.25.
In other Cerus Corporation news, insider Laurence M. Corash purchased 92,796 shares of the firm’s stock in a transaction on Friday, August 11th. The stock was bought at an average cost of $2.45 per share, with a total value of $227,350.20. Following the acquisition, the insider now directly owns 1,375,711 shares of the company’s stock, valued at $3,370,491.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 7.40% of the stock is owned by insiders.
Cerus Corporation Company Profile
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Receive News & Ratings for Cerus Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
